Dan Massey - Concepedia

Author

Dan Massey

Boehringer Ingelheim (United Kingdom)

Also Known As

D. Massey, D.G. Massey, Dan Massey, Massey, D

137

Publications

13.5K

Citations

H-Index

117

Concepts

All Affiliations

Boehringer Ingelheim (United Kingdom)Colorado State University National Taiwan University Hospital McGill University University of California, Los Angeles

About

Dan Massey is an author at Boehringer Ingelheim (United Kingdom) specializing in engineering, medicine, and computer science.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	19	28	1.1K
2	Medicine	19	24	6.6K
3	Health Sciences	7	7	570
4	Business	3	3	42
5	Social Sciences	3	3	734

Dan Massey

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Journal of Clinical Oncology	2013	3.2K
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi‐Long Wu, Caicun Zhou, Chengping Hu, The Lancet Oncology Lux-lung 6MedicineRandomised Phase 3PathologyBronchial Neoplasm	2014	2K
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, The Lancet Oncology Lux-lung 3Lux-lung 6MedicinePathologyBronchial Neoplasm	2015	1.6K
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, The Lancet Oncology OncologyPhase 2BPathologyBronchial NeoplasmAfatinib Versus Gefitinib	2016	1.1K
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial Paolo Barone, Werner Poewe, Stefan Albrecht, The Lancet Neurology PsychiatryPsychotropic MedicationDepressionPsychopharmacologyNeuropharmacology	2010	550
First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases Martin Schüler, Yi‐Long Wu, Vera Hirsh, Journal of Thoracic Oncology	2016	350
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With <i>EGFR</i> Mutations James Chih‐Hsin Yang, Vera Hirsh, Martin Schüler, Journal of Clinical Oncology Advanced Lung DiseaseCancer ManagementPathologyLife Questionnaire C30Tumor Biology	2013	319
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou, Annals of Oncology	2016	182
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto, Journal of Clinical Oncology Surgical OncologyCancer ManagementPathologyLux-lung 3Oncology	2012	171
An analysis of BGP multiple origin AS (MOAS) conflicts Xiaoliang Zhao, Dan Pei, Lan Wang, Network ScienceCross-border ManagementInternational RelationsService-level AgreementNetwork Analysis	2001	160

Page 1